Skip to main content
Dr. John Cush
@RheumNow
PMR: Spare The Steroids Please Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR https://t.co/dbrdVZRuoN
Audrey Gibson
@Gibson_RheumPAC
Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): A large real-world comparison found less steroid use with tirzepatide than semaglutide at 3 years: 27.2% vs 37.5%.@rheumnow #ACR2026 Abstract#2641
Audrey Gibson
@Gibson_RheumPAC
Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): Tirzepatide vs semaglutide in inflammatory arthritis: steroid use at 1 year was 19.1% vs 22.5% in matched cohorts. @rheumnow #ACR2026 Abstract#2641
Audrey Gibson
@Gibson_RheumPAC

Jamshaid et al: Tirzepatide vs semaglutide in inflammatory arthritis: 3-year steroid use was 27.2% vs 37.5%. Less treatment escalation is intriguing. @rheumnow #ACR2026 #ACRBest Abstract#2641

Jiha Lee
@JihaRheum
Can a structured program get PsA patients off prednisolone? A 3-step model: 1. GC education for patients and physicians 1. Individualized 12wk taper 3. Feedback line for adherence problems 26/46 (56.5%) stopped GC by 3mo. A#2303 @RheumNow #ACR26

PMR: Spare The Steroids Please

Daric A. Mueller, PA-C

Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR symptom relapse at a 6 milligram

Dr. John Cush
@RheumNow
The shifting sands of glucocorticoid use in SLE Despite the rapid development of emerging therapies for SLE, glucocorticoids remain an important component of disease management. "How well do our current corticosteroid prescribing habits align with current treatment guidelines?" https://t.co/kyZWVERLMP
×